Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-04-21

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-edited medicines for serious diseases and, with partners, commercializes approved and investigational CRISPR/Cas9-based therapies.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved Proof, Second Franchise Decides Upside

The approved therapy removes existential science risk, but the bigger rerating still depends on proving that an internally controlled program can become a durable second franchise. Strong cash reserves create time, yet the next 12-24 months remain unusually important.

Analysis

Thesis

Five-year upside comes from moving from one approved, partner-mediated therapy into a company with an established CASGEVY economics stream and one internally controlled franchise, most plausibly CTX310 or zugo-cel. The cash balance and March 2026 convert buy enough time for that second proof, but the stock still needs owned-program validation to earn a true platform rerating.

Last Economy Alignment

Cheaper AI should improve target selection, edit design and portfolio throughput, but value capture here still comes from regulated evidence, IP and manufacturing trust rather than software. That makes CRISPR Therapeutics a meaningful beneficiary of the Last Economy, though biology, regulation and treatment-network capacity remain the binding constraints.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.4x (from 5 most recent analyses)

Reasoning

The likely rerating is from cash-backed scientific optionality to a business with two value centers: a steadily scaling CASGEVY economics stream and at least one wholly owned asset that looks commercially real by 2028-2029. That supports solid value creation, but not a priced-for-perfection platform premium unless owned-program data become repeatable across several franchises.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The risk stack is still about proof, throughput and control. CASGEVY validates the modality, but realized shareholder value is throttled by Vertex leadership and transplant-network logistics, while the larger 2031 rerating needs a wholly owned program to show durable efficacy, manageable safety and credible commercial fit. The balance sheet reduces financing risk more than it reduces scientific, regulatory or timing risk.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

A refreshed April corporate deck reiterated more than 75 activated CASGEVY treatment centers globally and kept the 2026 milestone map intact, without disclosing a new owned-program efficacy readout.
The April 21 proxy filing was procedural and did not materially change capital allocation, governance posture or pipeline priorities.
No separate disclosure had confirmed pediatric CASGEVY filing initiation by the as-of date, so the next regulatory gate remained open rather than de-risked.

Forecast update

Runway improved after the convert, but no new wholly owned proof point arrived, so the medium-term value view only tightened modestly.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.39

They own gene-editing know-how, clinical evidence and regulated manufacturing steps that are hard to copy, so cheaper AI should help them create better shots on goal. But biology, regulators and treatment-center capacity still decide how much of that value they can actually turn into cash.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$83.74

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research